Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) (NCT04956640)

🧪 Interventions in This Study

• LY3537982 (DRUG)
• Pembrolizumab (DRUG)
• Cetuximab (DRUG)
• Pemetrexed (DRUG)
• Cisplatin (DRUG)
• Carboplatin (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (49 Sites)

Showing the first 25 of 49 sites.

• University of Alabama at Birmingham — Birmingham, Alabama
• USC Norris Cancer Hospital — Los Angeles, California
• Chao Family Comprehensive Cancer Ctr. — Orange, California
• Yale-New Haven Hospital — New Haven, Connecticut
• AdventHealth Orlando — Orlando, Florida
• Florida Cancer Specialists — Sarasota, Florida
• Indiana Univ Melvin & Bren Simon Cancer Center — Indianapolis, Indiana
• Community Health Network — Indianapolis, Indiana
• Mary Bird Perkins Cancer Center — Baton Rouge, Louisiana
• Massachusetts General Hospital — Boston, Massachusetts
• Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire
• NYU Langone Health- Long Island — Mineola, New York
• NYU Langone — New York, New York
• Memorial Sloan Kettering Cancer Center — New York, New York
• The University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
• Novant Health Cancer Institute - Elizabeth — Charlotte, North Carolina
• Novant Health Cancer Institute - Forsyth — Winston-Salem, North Carolina
• Fox Chase Cancer Center — Philadelphia, Pennsylvania
• UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
• Sarah Cannon Cancer Center — Nashville, Tennessee
• Vanderbilt Univeristy School of Medicine — Nashville, Tennessee
• South Texas Accelerated Research Therapeutics (START) — San Antonio, Texas
• START Mountain Region — West Valley City, Utah
• Inova Health System IRB — Fairfax, Virginia
• USO-Virginia Cancer Specialists, PC — Fairfax, Virginia

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Carcinoma, Non-Small-Cell Lung

• MYLUNG Consortium Study Protocol 2 — Daphne, Alabama
• A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) — Des Moines, Iowa
• THIO Sequenced With Cemiplimab in Advanced NSCLC — Birmingham, Alabama
• A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions — Duarte, California
• Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study — La Jolla, California
• A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) — Los Angeles, California

Explore by condition: All Carcinoma, Non-Small-Cell Lung clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.